Amorphous Sitagliptin Crystallization Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of sitagliptin suffer from poor bioavailability due to its crystalline state, leading to unpredictable therapeutic effects and stability issues, as amorphous forms are less stable and prone to crystallization.
Innovation Solution
Preparation of stable amorphous sitagliptin using a solution comprising sitagliptin and a crystallization inhibitor, such as polyvinylpyrrolidone, with microcrystalline cellulose as an excipient, through processes like solution loading or spray drying, to maintain stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If amorphous sitagliptin is used to improve bioavailability, then dissolution rate and absorption are enhanced, but stability deteriorates due to hygroscopicity and tendency to crystallize
Solution Approach 1:
The patent introduces a crystallization inhibitor as an intermediary substance that mediates between the amorphous sitagliptin and the crystalline state. This inhibitor prevents the amorphous form from transforming into crystalline forms, thereby maintaining stability while preserving the high bioavailability benefits of the amorphous state.
Solution Approach 2:
The patent creates a composite pharmaceutical composition that combines amorphous sitagliptin with a crystallization inhibitor. This composite material leverages the high dissolution rate of amorphous sitagliptin while the inhibitor component provides stability by preventing crystallization, thus resolving the contradiction between bioavailability and stability.
2Stability of the object's composition
If crystalline sitagliptin is used to improve stability, then compositional stability is enhanced, but bioavailability deteriorates due to poor dissolution rate
Solution Approach 1:
The patent changes the physical state parameter of sitagliptin from crystalline to amorphous, which fundamentally alters its dissolution characteristics. The amorphous form exhibits superior dissolution rate and bioavailability compared to the crystalline form, while the addition of a crystallization inhibitor maintains the stability needed for pharmaceutical use.
3Device complexity
If amorphous sitagliptin is prepared without a crystallization inhibitor to simplify the formulation, then device complexity is reduced, but stability deteriorates due to crystallization during storage
Solution Approach 1:
The crystallization inhibitor serves as a mediator that simplifies the overall formulation strategy by enabling the use of amorphous sitagliptin without requiring complex stabilization methods. This single additive component provides the necessary stability, avoiding the need for complex multi-component stabilization systems.
4Reliability
If amorphous sitagliptin is used to achieve consistent therapeutic effect, then therapeutic consistency is improved, but reliability deteriorates due to unpredictable absorption and patient variability
Solution Approach 1:
By changing the physical state from crystalline to amorphous, the patent fundamentally improves dissolution rate and absorption predictability. The amorphous form eliminates the variability associated with crystalline polymorphs, providing consistent therapeutic effects across different patients and conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a highly stable amorphous form of sitagliptin with low impurities, enhancing bioavailability and therapeutic consistency by inhibiting crystallization and improving stability.
Implementation Method 1
stable amorphous sitagliptin can be prepared from a solution comprising sitagliptin and a crystallization inhibitor
Implementation Method 2
stable amorphous sitagliptin can be prepared from a solution comprising sitagliptin and a crystallization inhibitor
Implementation Method 3
converting the solution provided in step a) into a particulate form
Data Source
AI summary
The present invention describes stable pharmaceutical compositions comprising amorphous sitagliptin and processes for their preparation. Pharmaceutical compositions are prepared from a solution comprising sitagliptin and a crystallization inhibitor.